Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.40 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.40 |
| ▸ | DPP9 | Q86TI2 | 4/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.33 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.33 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1439294 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3547377 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL729546 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3534892 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL3542501 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1303905 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL788022 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL589711 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL833267 | 0.98 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL3862327 | 0.98 | CHRNB2 (0.41) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 345 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120000654-A | Pharmaceutical composition added with pyruvate and preparation method and application thereof | 江苏长泰药业股份有限公司 | 2025-05-16 | — | — | CN | claimed |
| CN-120000654-A | Pharmaceutical composition added with pyruvate and preparation method and application thereof | 江苏长泰药业股份有限公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4551570-A1 | NOVEL COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | Dong-A ST Co., Ltd. (KR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025087383-A1 | COMPOUND ACTING AS PARP7 INHIBITOR | 深圳众格生物科技有限公司 | 2025-05-01 | — | — | WO | disclosed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| CN-119403798-A | Novel compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | 东亚ST 株式会社 | 2025-02-07 | — | — | CN | disclosed |
| CN-119212699-A | NLRP3 inhibitors | PTC医疗公司 | 2024-12-27 | — | — | CN | disclosed |
| EP-4479045-A2 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-12-25 | — | — | EP | disclosed |
| WO-2024235121-A1 | FUSED RING COMPOUND AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-11-21 | — | — | WO | disclosed |
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | BIONOVA PHARMACEUTICALS LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| EP-0927161-B1 | SUBSTITUTED CYCLIC AMINE METALLOPROTEASE INHIBITORS | PROCTER & GAMBLE (US) | 2002-10-16 | — | — | EP | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| US-6417219-B1 | ENZYME INHIBITORS AND OSTEOARTHRITIS | THE PROCTOR & GAMBLE COMPANY | 2002-07-09 | — | — | US | disclosed |
| US-20020072517-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2002-06-13 | — | — | US | disclosed |
| WO-2002044181-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
| US-20020061877-A1 | Substituted cyclic amine metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2002-05-23 | — | — | US | disclosed |
| EP-0912172-B1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | HOERRMANN WILHELM (DE) | 2000-09-06 | — | — | EP | disclosed |
| US-6066665-A | Combination of cis-4-hydroxy-L-proline and N-methyl-cis-4-hydroxy-L-proline for use as a therapeutic agent, in particular in cancer treatment | HOERRMANN WILHELM (DE) | 2000-05-23 | — | — | US | disclosed |
| EP-0912172-A1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | Hoerrmann, Wilhelm, Dr. (DE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1997033578-A1 | COMBINATION OF CIS-4-HYDROXY-L-PROLINE AND N-METHYL-CIS-4-HYDROXY-L-PROLINE FOR USE AS A THERAPEUTIC AGENT, IN PARTICULAR IN CANCER TREATMENT | HOERRMANN WILHELM (DE) | 1997-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317748-A1 | CARBONYL SUBSTITUTED DIAZASPIRO COMPOUNDS AND ITS USE | SDHA, PDHA1, GLS | CHRNB2 2185/4885CHRNA4 1829/4885CHRNB4 2744/4885 |
| US-20020061877-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | CHRNB2 4260/4885CHRNA4 4368/4885CHRNB4 4576/4885 |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | CHRNB2 4357/4885CHRNA4 3401/4885CHRNB4 3638/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | CHRNB2 3816/4885CHRNA4 4788/4885CHRNB4 4526/4885 |
| US-20020072517-A1 | Substituted cyclic amine metalloprotease inhibitors | CMA1, ADAM17, MMP25 | CHRNB2 4260/4885CHRNA4 4368/4885CHRNB4 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.